Simon Mitchell @mitchell.science · Dec 6 So, taking a step back, we have: - Different Achilles heel in each DLBCL - Different resistance mechanism mediated by complicated cross talk. This makes it really hard to improve treatments. We asked if we could break all the links with the TME by inhibiting non-canonical NF-kB?
0 likes 1 replies
?
Replies
Yes! Non-canonical NF-kB inhibition with Amgen16 overcomes all the microenvrionment mediated resistance we discovered, regardless of the mechanism! @amgen.bsky.social Let's summarise...